ArticleCureus2025
Nutritional Status as a Risk Factor for the Early Discontinuation of Inhaled Liposomal Amikacin in Mycobacterium avium Complex Pulmonary Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Amikacin Liposomal Inhalation Suspension: Advances in Application Against RefractoryInfection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary nontuberculous mycobacterial (NTM) disease, especially
methodsWe retrospectively analyzed patients with MAC-PD who received ALIS at Saitama Red Cross Hospital (November 2021-December 2024). Patients were categorized into early discontinuation (<6 months) and continuation (≥6 months) groups. Baseline data included age, sex, body mass index (BMI), albumin, comorbidities, pulmonary function, radiographic patterns, and co-infection status. Statistical tests included Welch's t-test, the Mann-Whitney U test, and Fisher's exact test.
resultsAmong 25 patients, 24% discontinued ALIS within six months. The early discontinuation group had significantly lower BMI (14.9±1.8 kg/m² vs. 19.0±3.3; p=0.002) and albumin (3.53±0.54 g/dL vs. 4.04±0.39; p=0.001). Fibrocavitary (FC) patterns were more frequent (50% vs. 11%;
conclusionsLow BMI, hypoalbuminemia, and FC radiographic patterns were significant risk factors for early ALIS discontinuation. These findings emphasize that maintaining adequate nutritional status is a prerequisite for successful multidrug antimicrobial therapy for pulmonary NTM disease. Clinicians should carefully evaluate these factors before starting ALIS and ensure close monitoring and nutritional support to improve adherence and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.